Skip to main content
IDYA logo

IDYA · IDEAYA Biosciences, Inc.

Track IDYA — free
$25.56 -0.61 (-2.33%) At close · Nov 20
Market Cap
$2.47B
Shares
96.69M
Volume · Nov 20 1.11M Avg daily vol (3M) 932.53K

Price & Indicators

 

Key stats

Close
$25.56
Fri 20 Nov
Open
$25.83
Fri 20 Nov
Average volume, 30 days
1.1M
shares a session
Short interest
8.2M
8.5% of shares · 8.9 days to cover
Day range
$25.46$26.87
Open $25.83 Close $25.56
52-week closing range
$25.56$42.48
Close $25.56 39.8% under the high
Short volume, last session
55%
Last earnings
Nov 4, 2024
Latest filing
10-Q · Nov 3
Price history
Jan 2020 to Nov 2026

Up next

call held Mar 15, 2022

Latest documents

2026
Nov 16
Investor event
Rolling NDA filed; registrational trials planned

IDEA Biosciences filed its first rolling NDA for derovacertib in the third quarter and anticipates acceptance in the first half of next year. It plans to start two registrational phase three studies by the end of the year.

6 source passages
Chief Executive Officer of IDEA Biosciences here, Ujira Hata We filed our first NDA Yes, so the NDA has been filed. We noted that that happened in the third quarter. That was also filed under RTOR, so a rolling review submission process of the NDA. We do believe derovacertib is relevant, irrespective of HLA-A2 status. So that is how we did proceed with the NDA filing with that specific mindset in place. So at the time of NDA acceptance, we do anticipate it will be likely in that first half of next year timeframe. our plan to start two registrational phase three studies by the end of the year Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Darovasertib combination NDA submitted for metastatic uveal melanoma

IDEAYA Biosciences submitted an NDA to the FDA for the darovasertib combination in metastatic uveal melanoma, stopped enrollment in OptimUM-010, and reported approximately $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026.

Revenue $10.24M ▼ 95.1% Net loss $125.75M Diluted EPS -$1.22
Read from the MD&A section
4 source passages
We are developing darovasertib for uveal melanoma (UM), a rare, aggressive form of ocular cancer, in both the metastatic and pre-metastatic settings of UM, as described below. During the third quarter, we successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program to support a potential U.S. approval of the darovasertib combination in mUM. Due to ongoing site activation and enrollment challenges, we have decided to stop enrollment and close the Phase 3 OptimUM-010 trial. As of September 30, 2026, we had cash, cash equivalents and marketable securities of approximately $1.15 billion, consisting primarily of money market funds, U.S. government securities, commercial paper and corporate bonds. Open the document at this passage
Nov 3
Current report 8-K
Darovasertib NDA submitted; OptimUM-010 closure targets $100-125 million savings

IDEAYA Biosciences completed its darovasertib NDA submission, stopped enrollment in OptimUM-010 to save $100-125 million, and reported a $125.7 million net loss with $1.15 billion in cash and marketable securities at September 30, 2026.

Financial results
4 source passages
During the third quarter IDEAYA successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to support a potential U.S. approval of the darovasertib combination in mUM under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program. Due to ongoing site activation and enrollment challenges, IDEAYA has decided to stop enrollment and close the Phase 3 OptimUM-010 trial. This is expected to result in estimated cost savings of $100-125 million that the company will reallocate towards other high-value programs in its pipeline, including potential registrational trials for IDE849 and IDE892. As of September 30, 2026, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.15 billion, compared to $1.24 billion as of June 30, 2026. The net loss for the three months ended September 30, 2026, was $125.7 million compared to the net loss of $112.5 million for the three months ended June 30, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$36.54M
Trailing 12 months
Net income (TTM)
−$420.01M
Trailing 12 months
Revenue growth YoY
-95.1%
Year over year
Operating margin
-72.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-14.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$838.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.8%
Year over year · more shares
Price change (1Y)
-22.9%
Trailing year
Short interest
8.5%
Latest settlement · 8.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −24%
below
Price vs 50-day avg −26%
below
RSI (14) 25
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −26%
trailing
6-month return −8%
trailing
YTD return −26%
this year
Relative strength +1%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $34 › 200d $34 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.52% of shares out · ▼ -9.3% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
284 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Strong
Revenue growth +3024%
Y/Y
EPS growth +62%
Y/Y
Free cash flow $-73.5M
Balance sheet $112.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −40%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 3, 2026
Estimated cost savings · $100M – $125M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−24% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
25 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $34 › 200d $34 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.52% of shares out · ▼ -9.3% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
284 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26 Now $26 · 0% Range high $42
vs 200-day avg -24% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities 1.24B As of June 30, 2026 —
Common stock sold under at-the-market offering program 1,196,423 the three months ended June 30, 2026 filing —
Net proceeds from sale of common stock through at-the-market offering program $33.1M Quarter ended June 30, 2026 —
Net proceeds from underwritten public offering and pre-funded warrants $323.4M Quarter ended June 30, 2026 —
Remaining balance for research and development services performance obligations $147M As of June 30, 2026 —
Total stock compensation expense $16.7M Three months ended June 30, 2026 —
Weighted average sales price per share under at-the-market offering $28.38 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IDYA
IDEAYA Biosciences, Inc.
this stock
$2.47B -26.1% +3024.4% — 8.5%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
284
% held
104.2%
Net QoQ
-1.5M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
268
View
Short & Settlement
Short Interest Falling
Shares short
8.2M
Days to cover
8.9d
Change
-843.0K sh
View
Short Volume
Short vol %
55%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
2.6K
Value
$90.9K
As of
Oct 21, 2026
View
Off-Exchange
Off-exchange %
43.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$218.7M
Net income (FY)
$-113.7M
EPS diluted
$-1.28
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
27

IDEA Biosciences filed its first rolling NDA for derovacertib in the third quarter and anticipates acceptance in the first half of next year. It plans to start two registrational phase three studies by the end of the year.

View
Proposed Sales
Value
$3.0M
Shares
75.0K
Filed
Aug 26, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
IDEAYA Biosciences Announces Deve…
Published
Nov 15, 2026
View

Performance

5D 20D 120D MTD YTD
IDYA -19.7% -26.4% -8.3% -20.0% -26.1%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -11.1% -17.1% +0.9% -11.3% -27.2%
Key facts CIK 1676725 CUSIP 45166A102 13F (30d) 297 filings 263 filers Visit website Investor relations